Predictive markers in bladder cancer: Do we have molecular markers ready for clinical use?

Critical Reviews in Clinical Laboratory Sciences

Volumn 51, Issue 5, 2014, Pages 291-304

  Sanguedolce, Francesca ^a   Bufo, Pantaleo ^a   Carrieri, Giuseppe ^a   Cormio, Luigi ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Immunohistochemistry; Pathology; Statistical analysis; Urinary malignancy

Indexed keywords

ALPHA CATENIN; ANGIOGENIC FACTOR; BETA CATENIN; BIOLOGICAL MARKER; CASPASE 3; CYCLIN D1; CYCLIN E; CYCLIN E1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; MOLECULAR MARKER; NERVE CELL ADHESION MOLECULE; P CADHERIN; PLAKOGLOBIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; SURVIVIN; THROMBOSPONDIN 1; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN C; VASCULOTROPIN D; TUMOR MARKER;

APOPTOSIS; BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CAPILLARY DENSITY; CHROMOSOMAL INSTABILITY; CHROMOSOME DELETION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; METASTASIS POTENTIAL; MICROSATELLITE INSTABILITY; MUSCLE INVASIVE BLADDER CANCER; NEOVASCULARIZATION (PATHOLOGY); NON MUSCLE INVASIVE BLADDER CANCER; NUMERICAL CHROMOSOME ABERRATION; OVERALL SURVIVAL; POINT MUTATION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; BLADDER TUMOR; IMMUNOHISTOCHEMISTRY;

HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84907443662     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2014.930412     Document Type: Review

References (247)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127: 2893-917.
2. Ferlay J, Randi G, Bosetti C, et al. Declining mortality from bladder cancer in Europe. BJU Int 2008;101:11-9.
3. Abdollah F, Gandaglia G, Thuret R, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 2013;37:219-25.
4. Messing EM. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Cambell's Urology, 8th ed. Philadelphia: Saunders, 2004:2737.
5. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239-49.
6. McDougal WS, Shipley WU, Kaufman DS, et al. Cancer of the bladder, ureter, and renal pelvis. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia: Lippincott Williams and Wilkins, 2008:1358-84.
7. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010; 28: 409-28.
8. Edge S, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer-Verlag, 2010:497-505.
9. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68: 549-53.
10. Babjuk M, Burger M, Zigeuner R, et al. Guidelines on Non-muscle Invasive Bladder Cancer (TaT1 and CIS). European Association of Urology. 2013. Available from http://www.uroweb.org/gls/pdf/05-TaT1-Bladder-Cancer-LR.pdf [last accessed 4 May 2014].
11. Witjes JA, Comperat E, Cowan NC, et al. Guidelines on Muscle- Invasive and Metastatic Bladder Cancer. European Association of Urology. 2013. Available from http://www.uroweb.org/gls/pdf/05-TaT1-Bladder-Cancer-LR.pdf [last accessed 4 May 2014].
12. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-77.
13. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009;182:2195-203.
14. Van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010;58: 433-41.
15. Fernandez-Gomez J, Madero R, Solsona E, et al; Club Urológico Espan?ol de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patients with nonmuscle- invasive bladder cancer treated with Bacillus Calmette- Guérin: external validation of the EORTC risk tables. Eur Urol 2011;60:423-30.
16. Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013;109:1460-6.
17. Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with Bacillus Calmette-Guérin. Eur Urol 2012;62:118-25.
18. Alkhateeb SS, Neill M, Bar-Moshe S, et al. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. Urol Ann 2011; 3:119-26.
19. Shah JB, McConkey DJ, Dinney PN. New strategies in muscleinvasive bladder cancer: on the road to personalized medicine. Clin Cancer Res 2011;17:2608-12.
20. Knowles MA, Elder PA, Williamson M, et al. Allelotype of human bladder cancer. Cancer Res 1994;54:531-8.
21. Tsai YC, Nichols PW, Hiti AL, et al. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990; 50:44-7.
22. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25:2685-96.
23. Fadl-Elmula I, Kytola S, Pan Y, et al. Characterization of chromosomal abnormalities in uroepithelial carcinomas by G-banding, spectral karyotyping and FISH analysis. Int J Cancer 2001;92:824-31.
24. Houskova L, Zemanova Z, Babjuk M, et al. Molecular cytogenetic characterization and diagnostics of bladder cancer. Neoplasma 2007;54:511-6.
25. Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2000;54:215-21.
26. Kawauchi S, Sakai H, Ikemoto K, et al. 9P21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. Hum Pathol 2009;40:1783-9.
27. Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9P21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 2003;23:41-8.
28. Mhawech-Faucelia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 2006; 106:1205-16.
29. Olumi AF, Tsai YC, Nichols PW, et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990;50:7081-3.
30. Presti Jr JC, Reuter VE, Galan T, et al. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 1991;51:5405-9.
31. Pycha A, Mian C, Posch B, et al. Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators? Urology 1999;53:1005-10.
32. Sardi I, Bartoletti R, Occhini I, et al. Microsatellite alterations in superficial and locally advanced transitional cell carcinoma of the bladder. Oncol Report 1999;6:901-5.
33. Kim W-J, Bae S-C. Molecular biomarkers in urothelial bladder cancer. Cancer Sci 2008;99:646-52.
34. Vaish M, Mandhani A, Mittal RD, Mittal B. Microsatellite instability as prognostic marker in bladder tumors: a clinical significance. BMC Urol 2005;5:2.doi:10.1186/1471-2490-5-2.
35. Sarosdy MF, Kahn PR, Ziffer MD, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006;176:44-7.
36. Maffezzini M, Campodonico F, Capponi G, et al. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res 2010;30: 4761-5.
37. Gofrit ON, Zorn KC, Silvestre J, et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008;26:246-9.
38. Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 2009;124:2899-904.
39. Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009;104:336-9.
40. Mian C, Lodde M, Comploj E, et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 2006;59:984-7.
41. Cheng L, Zhang S, MacLennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011;42:455-81.
42. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-25.
43. Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005;95:1344-50.
44. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-9.
45. Bolenz C, Shariat SF, Karakiewicz PI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 2010;106:1216-22.
46. Eissa S, Ali HS, Al Tonsi AH, et al. HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem 2005;38:142-8.
47. Gandour-Edwards R, Lara Jr PN, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95:1009-15.
48. Latif Z, Watters AD, Dunn I, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004; 40:56-63.
49. Leibl S, Zigeuner R, Hutterer G, Chromecki T, et al. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS 2008;116:27-32.
50. Mason RA, Morlock EV, Karagas MR, et al. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis 2009;30:1155-60.
51. Simonetti S, Russo R, Ciancia G, et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol 2009;17:198-205.
52. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007;25: 581-93.
53. Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 2010;16: 3011-8.
54. Miyake M, Sugano K, Sugino H, et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci 2010;101: 250-8.
55. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24: 3664-71.
56. Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5:e13821.
57. van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265-8.
58. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-21.
59. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11:4029-36.
60. van Rhijn BW, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64:1911-4.
61. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-12.
62. Wallerand H, Bakkar AA, de Medina SG, et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis 2005;26:177-84.
63. Park J, Song C, Shin E, et al. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with Bacillus Calmette-Guerin intravesical therapy? Urol Oncol 2013; 31:849-56.
64. Baselga J. New technologies in epidermal growth factor receptortargeted cancer therapy. Signal 2000;1:12-21.
65. Wells A. The epidermal growth factor receptor (EGFR) - a new target in cancer therapy. Signal 2000;1:4-11.
66. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
67. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985;1:366-8.
68. Villares GJ, Zigler M, Blehm K, et al. Targeting EGFR in bladder cancer. World J Urol 2007;25:573-9.
69. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990;50:2530-7.
70. Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994;101:166-76.
71. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, P53) expression and long-term prognosis. Br J Cancer 1994;69:1120-5.
72. Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995;153:919-25.
73. Ravery V, Grignon D, Angulo J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 1997;25:9-17.
74. Liukkonen T, Rajala P, Raitanen M, et al. Prognostic value of MIB1 score, P53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. Eur Urol 1999;36:393-400.
75. Popov Z, Gil-Diez-De-Medina S, Ravery V, et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004;22:93-101.
76. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7:2-8.
77. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003;46(Suppl):S85-104.
78. Kassouf W, Luongo T, Brown G, et al. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 2006; 176:787-92.
79. Philips GK, Halabi S, Sanford BL, et al; Cancer and Leukaemia Group B. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 2008;101:20-5.
80. Lipponen P, Eskelinen M, Syrjanen S, et al. Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 1991;20:238-42.
81. Lae M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010;21:815-9.
82. Fleischmann A, Rotzer D, Seiler R, et al. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 2011;60:350-7.
83. Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992;70:2493-8.
84. Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther 2010;10:407-15.
85. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005;62:309-17.
86. Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440-7.
87. Kruger S, Weitsch G, Buttner H, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002;102:514-8.
88. Kolla SB, Seth A, Singh MK, et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008;40:321-7.
89. Kruger S, Weitsch G, Buttner H, et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 2002;21:981-7.
90. Kassouf W, Black PC, Tuziak T, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008;179:353-8.
91. Mellon JK, Lunec J, Wright C, et al. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996;155:321-6.
92. Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7: 1957-62.
93. Liedberg F, Anderson H, Chebil G, et al. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 2008;26:17-24.
94. Underwood M, Bartlett J, Reeves J, et al. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995;55:2422-30.
95. Hussain M, Smith DC, Al-Sukhun S, et al. Preliminary results of HER-2/neu screening and treatment with trastuzumab (Herceptin) (T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in patients with advanced urothelial cancer. In: Proceedings of the American Society of Clinical Oncology, 38th Annual Meeting, 2002. May 18-21. Abstract no. 800.
96. Hussain MH, MacVicar GR, Petrylak DP, et al; National Cancer Institute. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218-24.
97. Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6:678-86.
98. Esrig D, Spruck CH III, Nichols PW, et al. P53 nuclear protein accumulation correlates with mutations in the P53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143: 1389-97.
99. Watanabe J, Nishiyama H, Okubo K, et al. Clinical evaluation of P53 mutations in urothelial carcinoma by IHC and FASAY. Urology 2004;63:989-93.
100. McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of P53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 2000; 6:1854-64.
101. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388-92.
102. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear P53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:1259-64.
103. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of P53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384-90.
104. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of P53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85:53-9.
105. Garcia del Muro X, Condom E, Vigues F, et al. P53 and P21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004;100:1859-67.
106. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1- S modulators (P53, P21Waf1, P27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 2004;45:606-12.
107. Tzai TS, Tsai YS, Chow NH. The prevalence and clinicopathologic correlate of P16INK4a, retinoblastoma and P53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol 2004;22:112-8.
108. Shariat SF, Bolenz C, Karakiewicz PI, et al. P53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int 2010;105:489-95.
109. Dalbagni G, Parekh DJ, Ben-Porat L, et al. Prospective evaluation of P53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 2007;99:281-5.
110. Ecke TH, Sachs MD, Lenk SV, et al. TP53 gene mutations as an independent marker for urinary bladder cancer progression. Int J Mol Med 2008;21:655-61.
111. Esrig D, Elmajian D, Groshen S, et al. P53 and the treatment of bladder cancer. Nature 1997;385:123-4.
112. Fleshner N, Kapusta L, Ezer D, et al. P53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 2000;164:1177-82.
113. Lipponen PK. Overexpression of P53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-70.
114. Lianes P, Charytonowicz E, Cordon-Cardo C, et al. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. Clin Cancer Res 1998;4:1267-71.
115. Schmitz-Draüger BJ, Goebell PJ, Ebert T, Fradet Y. P53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000;38:691-9;discussion 700
116. Tokunaga H, Shariat SF, Green AE, et al. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys 2001; 51:16-22.
117. Schrier BP, Vriesema JLJ, Witjes JA, et al. The predictive value of P53, P27Kip1, and a-catenin for progression in superficial bladder carcinoma. Eur Urol 2006;50:76-82.
118. Goebell PJ, Groshen SG, Schmitz-Drager BJ. P53 immunohistochemistry in bladder cancer - a new approach to an old question. Urol Oncol 2010;28:377-88.
119. Bolenz C, Lotan Y. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat Clin Pract Urol 2008;5:676-85.
120. Llopis J, Alcaraz A, Ribal MJ, et al. P53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol 2000;37:644-53.
121. Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J, Nogueira-March JL. P53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 2002;41:182-8;discussion 188-9.
122. Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009;182: 78-84.
123. Shariat SF, Zlotta AR, Ashfaq R, et al. Cooperative effect of cellcycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007;20:445-59.
124. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007;177:481-7;discussion 487.
125. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006;37: 1568-76.
126. Shariat SF, Lotan Y, Karakiewicz PI, et al. P53 Predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009;182: 907-13.
127. Dahse R, Gartner D, Werner W, et al. P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences. Oncol Rep 2003;10:2033-7.
128. Suttmann H, Riemensberger J, Bentien G, et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006;66:8250-7.
129. Kaempfer R, Gerez L, Farbstein H, et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 1996;14:1778-86.
130. Zlotta AR, Noel JC, Fayt I, et al. Correlation and prognostic significance of P53, P21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with Bacillus Calmette-Guerin intravesical therapy. J Urol 1999;161:792-8.
131. Saint F, Le Frere Belda M-A, Quintela R, et al. Pretreatment P53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guerin (BCG). Eur Urol 2004;45:475-82.
132. Peyromaure M, Weibing S, Sebe P, et al. Prognostic value of P53 overexpression in T1G3 bladder tumors treated with Bacillus Calmette-Guerin therapy. Urology 2002;59:409-13.
133. Moonen PM, van Balken-Ory B, Kiemeney LA, et al. Prognostic value of P53 for high risk superficial bladder cancer with longterm followup. J Urol 2007;177:80-3.
134. Lacombe L, Dalbagni G, Zhang ZF, et al. Overexpression of P53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guérin therapy: correlation to clinical outcome. J Clin Oncol 1996;14: 2646-52.
135. Palou J, Algaba F, Vera I, et al. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance Bacillus Calmette-Guerin. Eur Urol 2009;56:829-36.
136. Esuvaranathan K, Chiong E, Thamboo TP, et al. Predictive value of P53 and PRB expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007;109: 1097-105.
137. Lebret T, Becette V, Barbagelatta M, et al. Correlation between P53 over expression and response to Bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998;159:788-91.
138. George B, Datar RH, Wu L, et al. P53 gene and protein status: the role of P53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007;25:5352-8.
139. De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH. Cytokine gene expression in a mouse model: the first instillations with viable Bacillus Calmette-Guerin determine the succeeding Th1 response. J Urol 2003;170:2004-8.
140. Kakehi Y, Ozdemir E, Habuchi T, et al. Absence of P53 overexpression and favorable response to cisplatin-based neo-adjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res 1998;89:214-20.
141. Jankevicius F, Goebell P, Kushima M, et al. P21 and P53 immunostaining and survival following systemic chemotherapy for urothelial cancer. Urol Int 2002;69:174-80.
142. Cote RJ, Esrig D, Groshen S, et al. P53 and treatment of bladder cancer. Nature 1997;385:123-5.
143. Sengelov L, Horn T, Steven K. P53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J Cancer Res Clin Oncol 1997;123: 565-70.
144. Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on P53 status. J Clin Oncol 2011;29:3443-9.
145. Ogura K, Habuchi T, Yamada H, et al. Immunohistochemical analysis of P53 and proliferating cell nuclear antigen (PCNA) in bladder cancer positive immunostaining and radiosensitivity. Int J Urol 1995;2:302-8.
146. Osen I, Fossa SD, Majak B, et al. Prognostic factors in muscleinvasive bladder cancer treated with radiotherapy: an immunohistochemical study. Br J Urol 1998;81:862-9.
147. Pollack A, Wu CS, Czerniak B, et al. Abnormal BCL-2 and PRB expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 1997;3: 1823-9.
148. Rotterud R, Berner A, Holm R, et al. P53, P21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. BJU Int 2001;88:202-8.
149. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent PRB expression is associated with bladder cancer progression and has cooperative effects with P53. Cancer Res 1998;58:1090-4.
150. Cormio L, Tolve I, Annese P, et al. Retinoblastoma protein expression predicts response to Bacillus Calmette-Guerin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol 2010;28:285-9.
151. Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251-6.
152. Lee K, Jung ES, Choi YJ, et al. Expression of PRB, P53, P16 and cyclin D1 and their clinical implications in urothelial carcinoma. J Korean Med Sci 2010; 25:1449-55.
153. Logothetis CJ, Xu HJ, Ro JY, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992;84:1256-61.
154. Cormio L, Tolve I, Annese P, et al. Altered P53 and PRB expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 2009;29:4201-4.
155. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008;18:1-8.
156. Harada K, Ogden GR. An overview of the cell cycle arrest protein, P21(WAF1). Oral Oncol 2000;36:3-7.
157. Lipponen P, Aaltomaa S, Eskelinen M, et al. Expression of P21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value. Eur Urol 1998;34:237-43.
158. Shariat SF, Kim J, Raptidis G, et al. Association of P53 and P21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003;61:1140-5.
159. Migaldi M, Sgambato A, Garagnani L, et al. Loss of P21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 2000;6:3131-8.
160. Liukkonen T, Lipponen P, Raitanen M, et al. Evaluation of P21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res 2000;28: 285-92.
161. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of P21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-9.
162. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112:315-25.
163. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010;183:68-75.
164. Korkolopoulou P, Christodoulou P, Konstantinidou AE, et al. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on P27Kip1. Hum Pathol 2000;31:751-60.
165. Sgambato A, Migaldi M, Faraglia B, et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced diseasefree survival in primary superficial bladder cancers. Cancer Res 1999;59:3245-50.
166. Kamai T, Takagi K, Asami H, et al. Decreasing of P27(Kip1) and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001;84: 1242-51.
167. Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000;157: 787-94.
168. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators P27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999;155:1129-36.
169. Wagner U, Suess K, Luginbuhl T, et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999;188:44-50.
170. Lopez-Beltran A, Requena MJ, Luque RJ, et al. Cyclin D3 expression in primary Ta/T1 bladder cancer. J Pathol 2006;209: 106-13.
171. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of P53, P21, and PRB expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007-13.
172. Grossman HB, Liebert M, Antelo M, et al. P53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998;4: 829-34.
173. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of P53 and PRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217-21.
174. Benedict WF, Lerner SP, Zhou J, et al. Level of retinoblastoma protein expression correlates with P16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999;18:1197-203.
175. Jin JO, Lehmann J, Taxy J, et al. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer 2006;5: 150-4.
176. Shariat SF, Tokunaga H, Zhou J, et al. P53, P21, PRB, and P16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22:1014-24.
177. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17:2941-53.
178. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285: 324-8.
179. Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171:626-30.
180. Schultz IJ, Kiemeney LA, Karthaus HF, et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 2004;50:1425-8.
181. Shariat SF, Ashfaq R, Karakiewicz PI, et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007;109:1106-13.
182. Schultz IJ, Kiemeney LA, Witjes JA, et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003;23:3327-31.
183. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8:128-36.
184. Shariat SF, Karakiewicz PI, Godoy G, et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res 2009;15: 7012-9.
185. Karam JA, Lotan Y, Ashfaq R, et al. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 2007;70:482-6.
186. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008; 26:59-65.
187. Kong G, Shin KY, Oh YH, et al. BCL-2 and P53 expressions in invasive bladder cancers. Acta Oncol 1998;37:715-20.
188. Stavropoulos NE, Filiadis I, Ioachim E, et al. Prognostic significance of P53, BCL-2 and Ki-67 in high risk superficial bladder cancer. Anticancer Res 2002;22:3759-64.
189. Shiina H, Igawa M, Urakami S, et al. Immunohistochemical analysis of BCL-2 expression in transitional cell carcinoma of the bladder. J Clin Pathol 1996;49:395-9.
190. Rodel C, Grabenbauer GG, Rodel F, et al. Apoptosis, P53, BCL-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000;46:1213-21.
191. Ong F, Moonen LM, Gallee MP, et al. Prognostic factors in transitional cell cancer of the bladder: an emerging role for BCL-2 and P53. Radiother Oncol 2001;61:169-75.
192. Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and P27 as predictors of invasive bladder cancer. N Engl J Med 2000;343: 1418-20.
193. Svatek RS, Herman MP, Lotan Y, et al. Soluble Fas-A promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006;106:1701-7.
194. Giannopoulou I, Nakopoulou L, Zervas A, et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res 2002;30:342-5.
195. Yamana K, Bilim V, Hara N, et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005;93: 544-51.
196. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603-12.
197. Bochner BH, Esrig D, Groshen S, et al. Relationship of tumor angiogenesis and nuclear P53 accumulation in invasive bladder cancer. Clin Cancer Res 1997;3:1615-22.
198. Youssef RF, Mitra AP, Bartsch Jr G, et al. Molecular targets and targeted therapies in bladder cancer management. World J Urol 2009; 27:9-20.
199. Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: association with P53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219-27.
200. Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000;6: 4866-73.
201. Streeter EH, Harris AL. Angiogenesis in bladder cancer - prognostic marker and target for future therapy. Surg Oncol 2002;11:85-100.
202. Shariat SF, Youssef RF, Gupta A, et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010;183:1744-50.
203. Shariat SF, Karakiewicz PI. Molecular markers for bladder cancer staging and prognosis. In: Soloway M, Khoury S, eds. Bladder Cancer, 2nd ed. Paris: ICUD-EAU - Editions 21, 2012:217.
204. Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995; 154: 69-71.
205. Zu X, Tang Z, Li Y, et al. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int 2006;98:1090-3.
206. Miyata Y, Kanda S, Ohba K, et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res 2006;12:800-6.
207. Crew JP, O'Brien T, Bicknell R, et al. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999;161:799-804.
208. Jeon SH, Lee SJ, Chang SG. Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. Oncol Rep 2001;8:1265-7.
209. Chow NH, Liu HS, Chan SH, et al. Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res 1999;19:4593-7.
210. Stavropoulos NE, Bouropoulos C, Ioachim IE, et al. Prognostic significance of angiogenesis in superficial bladder cancer. Int Urol Nephrol 2004;36:163-7.
211. Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep 2009;11:244-9.
212. Youssef RF, Lotan Y. Predictors of outcome of non-muscleinvasive and muscle-invasive bladder cancer. Sci World J 2011;11: 369-81.
213. Osai WE, Ng CS, Pagliaro LC. Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs 2008;19:427-9.
214. Watanabe H, Hori A, Seno M, et al. A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun 1991;175:229-35.
215. Miyake H, Hara I, Gohji K, et al. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 1998;123:121-6.
216. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by P53 regulation of thrombospondin-1. Science 1994;265:1582-4.
217. Cohen MB, Waldman FM, Carroll PR, et al. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol 1993; 24: 772-8.
218. Kruger S, Mahnken A, Kausch I, Feller AC. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 2005;47:463-7.
219. Margulis V, Lotan Y, Karakiewicz PI, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009;101: 114-9.
220. Margulis V, Shariat SF, Ashfaq R, et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12:7369-73.
221. Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59:83-8.
222. Ramos D, Ruiz A, Morell L, et al. Prognostic value of morphometry in low grade papillary urothelial bladder neoplasms. Anal Quant Cytol Histol 2004;26:285-94.
223. Stavropoulos NE, Ioackim-Velogianni E, Hastazeris K, et al. Growth fractions in bladder cancer defined by Ki67: association with cancer grade, category and recurrence rate of superficial lesions. Br J Urol 1993;72:736-9.
224. Santos L, Amaro T, Costa C, et al. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer 2003;105: 267-72.
225. Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers P53, MDM2, P21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5:4079-84.
226. Gontero P, Casetta G, Zitella A, et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000;38:287-96.
227. Lebret T, Becette V, Hervé J-M, et al. Prognostic value of MIB1 antibody labeling index to predict response to Bacillus Calmette- Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000;37:654-9.
228. Behnsawy HM, Miyake H, Abdalla MA, et al. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. Urol Oncol 2011; 29:495-501.
229. Clairotte A, Lascombe I, Fauconnet S, et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 2006;125:119-26.
230. Bryan RT, Atherfold PA, Yeo Y, et al. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol 2008;215:184-94.
231. Jang TJ, Cha WH, Lee KS. Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. Virchows Arch 2010;457:319-28.
232. Koksal IT, Ates M, Danisman A, et al. Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma. Pathol Oncol Res 2006; 12:13-9.
233. Bringuier PP, Umbas R, Schaafsma HE, et al. Decreased Ecadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993;53:3241-5.
234. Syrigos KN, Harrington K, Waxman J, et al. Altered gammacatenin expression correlates with poor survival in patients with bladder cancer. J Urol 1998;160:1889-93.
235. Byrne RR, Shariat SF, Brown R, et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001;165: 1473-9.
236. Mhawech-Fauceglia P, Fischer G, Beck A, et al. Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 2006; 32:439-44.
237. Lascombe I, Clairotte A, Fauconnet S, et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res 2006;12:2780-7.
238. Kashibuchi K, Tomita K, Schalken JA, et al. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 2007;14: 789-94.
239. Nonomura N, Nakai Y, Nakayama M, et al. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer. Int J Clin Oncol 2006;11:297-302.
240. Aoki S, Yamada Y, Nakamura K, et al. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer. Oncol Rep 2006;16: 279-84.
241. Comperat E, Camparo P, Haus R, et al. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch 2007;450:419-24.
242. Bufo P, Sanguedolce F, Tortorella S, et al. Expression of mitotic kinases phospho-aurora A and aurora B correlates with clinical and pathological parameters in bladder neoplasms. Histol Histopathol 2010;25:1371-7.
243. Shirahama T, Arima J, Akiba S, Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001;92:188-93.
244. Shariat SF, Kim JH, Ayala GE, et al. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 2003;169:938-42.
245. Kim SI, Kwon SM, Kim YS, Hong SJ. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 2002;60:816-21.
246. Xylinas E, Kluth LA, Lotan Y, et al. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. Urol Oncol 2014;32:230-42.
247. Cheng L, Davison DD, Adams J, et al. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 2014;89:73-111.